多数公司触及"净利润为负且营收不到3亿元"的情形 随着2024年报披露，退市新规威力大显。 据不完全统计，4月28日有6家上市公司被实施退市风险警示，29日还将有14家被披星戴帽，这20家公司 均触及财务类退市风险，多数公司触及"净利润为负且营收不到3亿元"的情形。 根据上市公司公告粗略统计，今年以来被实施退市风险警示的公司中，还有10余家触及"净利润为负且 营收不到3亿元"的情形。另有多家公司因为2024年末净资产为负值，被实施退市风险警示。还有些公司 预计触及上述情形，可能被*ST。 近年来存在一个较为普遍的现象，就是面临财务指标、重大违法等情形被强制退市的公司，最终率先被 投资者用脚投出市场。 南开大学金融发展研究院院长田利辉认为，财务指标趋严是退市新规核心，财务类退市将成为主流， 2025年预计有30～40家企业因此退市；同时，规范类、重大违法类退市同步强化，形成多元退市格局。 他称，退市新规的严格执行，标志着A股从"重融资"向"重投资"转型，通过财务指标、交易规则、违法 惩处的多维约束，推动市场形成"有进有出、优胜劣汰"的良性循环。 多数公司触及财务类退市风险 4月28日，6家上市公司被实施退市风险 ...

Core Viewpoint - Puli Pharmaceutical has officially entered the delisting preparation period due to serious financial fraud, marking a significant case of forced delisting in the A-share market [2][7]. Group 1: Company Overview - Puli Pharmaceutical, once a star in the pharmaceutical industry with a stock price exceeding 100 yuan, has faced severe penalties for financial misconduct, leading to its delisting [2][9]. - The company reported a dramatic decline in net profit from 4.08 billion yuan in 2020 to a loss of 982.7 million yuan in 2023, indicating a hollowing out of actual performance after excluding fraudulent activities [9]. Group 2: Financial Fraud Details - The China Securities Regulatory Commission (CSRC) found that Puli Pharmaceutical inflated its revenue by 1.029 billion yuan and profits by 669 million yuan over two years, accounting for 73.83% of the disclosed profits during that period [7]. - In 2021, the company falsely reported 514 million yuan in revenue (34.07% of that year's disclosed revenue) and 290 million yuan in profit (62.06% of disclosed profit) [7]. - In 2022, the inflated figures were 515 million yuan in revenue (28.51%) and 379 million yuan in profit (86.36%) [7]. Group 3: Market Reaction - On the first day of the delisting preparation period, the stock price of Puli Pharmaceutical plummeted by 77%, closing at 0.65 yuan per share, with a total market value shrinking to 365 million yuan, a loss of over 20 billion yuan from its peak [3][9]. - The convertible bonds issued by Puli also experienced a significant drop, with an intraday decline of 33.72% [5]. Group 4: Regulatory Actions - The CSRC imposed a fine of 10 million yuan on Puli Pharmaceutical, with the chairman and other executives facing substantial penalties and market bans [8]. - The new delisting regulations have led to increased scrutiny, with over 30 ST stocks facing similar fates, indicating a tightening of financial and regulatory standards in the market [11].

Core Viewpoint - The recent downturn in micro-cap stocks, which had previously led the market rally, is attributed to multiple factors including regulatory changes, earnings concerns, and market dynamics [1][4][5]. Group 1: Market Performance - The Wind micro-cap stock index saw a year-to-date increase of over 20% until March 20, 2023, but faced significant pullbacks afterward, impacting related funds [3]. - Funds heavily invested in micro-cap stocks experienced an average gain of 12.72% from the beginning of the year to March 20, followed by an average decline of nearly 3% in the subsequent week [3]. Group 2: Factors Influencing Micro-Cap Stocks - The new delisting regulations are causing concerns about the stability of smaller companies, leading to fears of potential delistings or ST (special treatment) designations [4]. - There are worries regarding annual report performance, as the effects of economic stabilization policies may take time to reflect in company earnings, prompting early sell-offs by investors [4]. - The significant prior gains in micro-cap stocks have led to a decline in valuations as investor risk appetite decreases [4]. Group 3: Market Dynamics and Strategies - The recent adjustments in micro-cap stocks are partly attributed to a calendar effect, with April being a peak month for annual report releases and potential delistings [4]. - The volatility in micro-cap stocks is seen as a normal part of market fluctuations, although the current environment and technological advancements have made this period different from early 2024 [5]. - Concerns about high-frequency trading and quantitative strategies exacerbating market declines are noted, but some experts argue that these strategies can also provide liquidity and stabilize the market [6][7]. Group 4: Investment Strategies and Opportunities - Fund managers are innovating strategies to manage volatility, such as maintaining a constant stock-bond ratio and employing barbell strategies to balance portfolios [11]. - There is recognition of the long-term investment value in micro-cap stocks, as many are overlooked and may contain significant growth potential [12][13]. - The current economic transition and technological advancements present opportunities for micro-cap stocks in sectors like AI, semiconductor equipment, and automation [14].